Published in

American Association for the Advancement of Science, Science, 6477(367), p. 586-590, 2020

DOI: 10.1126/science.aax5863

Links

Tools

Export citation

Search in Google Scholar

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Taking preventive measures Recent technological advances have made it possible to detect, in healthy individuals, premalignant blood cells that are likely to progress to hematologic cancer. These advances in early detection have fueled interest in “cancer interception,” the idea that drugs designed to treat advanced cancer might also be useful for cancer prevention. Uckelmann et al. now provide support for this concept in a study of mice genetically predisposed to develop acute myeloid leukemia. Early administration of an epigenetic therapy that had previously been shown to have anticancer activity in advanced leukemia models was able to eliminate preleukemia cells and extend survival of the mice. Science , this issue p. 586